Friday, November 20, 2020 12:08:46 PM
Thank you for your comments. It is always very beneficial to consider different perspectives. The points raised are valid and relevant. Nonetheless, in my opinion they are of a “more temporary” nature (in absolute terms only death is permanent) and do not raise to the level where they detract from the investment thesis I endorse (described in my initial posting).
The thesis rests on “more permanent” elements that, if correct, should in due course result in a “normalized activity” (read: growing number of contributing programs, growing Plasma card loads) that drives “normalized financials” (read: absence of accounting revenue reversals), which in turn drive the stock to higher price levels.
During the investment horizon there will be unexpected events, some negative (like COVID, new accounting policies, government fiscal programs, etc.), some positive (like the increase in donation compensation rates, positive competitive windfall due to the Wirecard event). Some of these may be judged significant, for sure, but still do not raise to the level of impacting the fundamentals in the thesis.
Some unexpected negative events support pessimistic business narratives with major loss in the price of the stock (witness the 30%+ drop in the price on 3Q20 earnings announcement). Often, there is a “pile in” effect, where investors (and analysts) add gloom at will depressing the price further. It is on these times where the investor’s ability (read rational conviction) to see “normalized activity” is at a premium.
Thank you again, and thank you for your good wishes.
Recent PAYS News
- Paysign to Host First Quarter 2024 Earnings Call • Business Wire • 04/09/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17 • Business Wire • 03/14/2024 08:30:00 PM
- Paysign, Inc. Reinforces Payment Processing Acumen With New Executive Hire • Business Wire • 03/13/2024 08:30:00 PM
- Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29 • Business Wire • 03/12/2024 08:30:00 PM
- Paysign Inc. to Sponsor the 2024 ACCESS USA Conference March 19-21 • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:22:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:14:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:07:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 12:51:22 PM
- Paysign to Host Fourth Quarter and Full Year 2023 Earnings Call • Business Wire • 02/27/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:55:56 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 05:36:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:50:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:44:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:57:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 11:49:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:50:43 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:26:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2024 12:03:20 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 12:56:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/02/2023 09:44:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM